Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...

Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court ...

Nov 13 (Reuters) - Eli ... in Lilly's diabetes drug Mounjaro and weight-loss treatment Zepbound - could prevent one new case of diabetes for every nine patients treated. The company initially ...

Eli Lilly has announced that the company will present data from studies ... delivery of prescription medications and other health products. *Revenue and Net Income in Billions Since 2016, Eli ...